Up next

Autoplay

Dr. Aleksander Sekulic on Vismodegib in Patients with Basal Cell Nevus Syndrome

1 Views • 07/01/23
Share
Embed
administrator
administrator
Subscribers
0

Aleksandar Sekulic, MD, PhD, Assistant Professor of Dermatology, Mayo Clinic, Scottsdale, AZ, explains the positive data that came from a recent study of the hedgehog pathway inhibitor vismodegib. Vismodegib decreased the size of existing basal cell carcinomas and reduced the number of new basal cell carcinomas in patients with basal cell nevus syndrome (Gorlin syndrome).

For more information visit: http://targetedhc.com/

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay